Evidence map›Paper›PMID 40802944›Full record

ReviewThe New England journal of medicine2025

Metabolic Dysfunction-Associated Steatotic Liver Disease.

Giovanni Targher, Luca Valenti, Christopher D Byrne

Registry-linked trialAbstract readReview
PubMed Publisher
In one paragraph

Review in The New England journal of medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07713992 (Efficacy and Safety of Mazdutide in Patients With Type 2 Diabetes Mellitus and Moderate to Severe Nonalcoholic Fatty Liver Disease Previously Treated With Semaglutide), which is not on this map. Cited by 194 papers, 7 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
194citing papers in PubMed, 7 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT07713992 nanot yet recruitingstarted 2026, after this paper: background citation

Efficacy and Safety of Mazdutide in Patients With Type 2 Diabetes Mellitus and Moderate to Severe Nonalcoholic Fatty Liver Disease Previously Treated With Semaglutide: A Multicenter, Prospective, Randomized Controlled Trial (IIT)

Ran2026Enrolled72Registered outcomes20Posted comparisons0ConditionsNonalcoholic Fatty Liver Disease (NAFLD) With History of Diabetes Melitus, Type 2 Diabetes Mellitus (T2DM)ArmsMazdutide(Dual GLP-1R/GCGR Agonist), Semaglutide (1 Mg Dose)
PMID 23999198PMID 34713962PMID 39431379PMID 34310013PMID 33880754PMID 31604171PMID 39809974PMID 40491239PMID 20957001PMID 35013484PMID 31405212PMID 29221645other papers from this trial
Open the trial in the graph
3 · Its place in the literature

Who cites it

194 citing papers in PubMed, 7 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Effects of GLP-1 Receptor Agonists on Muscle Mass, Strength, and Quality in MASLD: A Systematic Review.Liver international : official journal of the International Association for the Study of the Liver · 2026
    Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Article
  9. Article
  10. Review
  11. Review
  12. Article
  13. Review
  14. Review
  15. Article
  16. Article
  17. Review
  18. Review
  19. Review
  20. Article

134 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Giovanni TargherDepartment of Medicine, University of Verona, Verona, Italy.ORCID 0000-0002-4325-3900
Luca ValentiDepartment of Pathophysiology and Transplantation, University of Milan, Milan.ORCID 0000-0001-8909-0345
Christopher D ByrneNational Institute for Health and Care Research, Southampton Biomedical Research Centre, University Hospital Southampton, Southampton, United Kingdom.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID40802944

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.